Back to EZorb Newsletter Index

In this issue:

1. Share Success: Letters From Readers
2. Research News: Inflammatory Diseases May Delay/Reduce Antibody Response To COVID-19 Vaccination
3. Useful Links
4. What Are Others Saying About EZorb and Marvlix?

Letter I: From Doreen D.
Received at Testimonial Submit Form Sunday, March 28, 2021 at 07:01:37
(Unedited)

I've suffered from arthritis for years. It started really ramping up when I was in my late 50's. mostly my hands, knees and left hip.

I'm not at all a medical doctor junkie. I say that with respect for the medical field and I do believe there are times when medical help is needed however, being from the medical field I also know that once you get tied up in all those drugs they want to give you, it's very hard to ever get out.

That being said, I was really at the end of my rope. I tried everything. I exercise, don't smoke, don't drink, no dairy, no processed sugars, no gluten, supplement after supplement and nothing helped much.

I took over the counter pain meds too but found they didn't do much and I kept needing more. Every day I asked God to please heal me. I completely believe that anything is possible with the Lord's help. He will show you the way.

So one day I opened my emails and there it was. EZorb. I had no idea what it was or how it worked. I began to research it. It made total sense.

I'm here to tell you I'm 67 years old and I have my life back! The healing and change was unbelievable. The pain in my knees and hip is gone. I still have a little in my hands but it's so manageable. No pain meds ever!

I still live a healthy life which I believe you need to do as well but I will forever be grateful for this product. I take it twice a day and its been about 8 months now. I will tell you this I'll never be without this amazing life changing product!

If you are struggling with the same things, try it. Get off the meds, they only mask your problem. EZorb will definitely help.

Thank you, thank you, thank you EZorb!

This newsletter is now read by over 120,000 subscribers worldwide. Success stories you have contributed over the years have had a great impact on many people's life.

Please email your story to sharesuccess @ ezorbonline.com or simply post it at Testimonial Submit Form. Your personal information will never be revealed to the public.

SARS-CoV-2 vaccination “essentially works” in people with immune-mediated inflammatory diseases (IMIDs), but humoral immune responses may be delayed and reduced, researchers report.

These findings are based on an analysis of 84 patients with IMIDs - including spondyloarthritis (32.1%), rheumatoid arthritis (29.8%), systemic rheumatic diseases (19.1%), inflammatory bowel disease (9.5%), and psoriasis (9.5%) - and 182 healthy controls. All participants had been given at least one dose of the Pfizer-BioNTech (BNT162b2) vaccine at least 10 days previously, with the majority (96.0%) having received both doses, and all patients had tested negative for SARS-CoV-2 antibodies prior to their first dose.

All healthy controls developed antibodies to the S1 domain of the spike protein of SARS-CoV-2 and were categorized as responders, but five (6%) patients with IMIDs did not respond to vaccination, with lack of immunogenicity at 11, 27, and 39 days after the second dose in three of these individuals. Antibody positivity was defined as an optical density (OD) of 0.8 units or more when determined at 450 nm using a commercial ELISA assy.

Georg Schett (Friedrich-Alexander University Erlangen-Nuremberg, Germany) and team then measured the development of neutralizing antibodies using an assay measuring the ability of anti-SARS-CoV-2 antibodies to block the binding of the SARS-CoV-2 receptor-binding domain to ACE2. They found that a significantly smaller proportion of IMID patients versus controls developed neutralizing antibodies, at 90.5% versus 99.5%.

“Thus, roughly 1 out of 10 patients with IMID fails to develop neutralizing antibodies after SARS-CoV-2 vaccination, while it is only 1 out of 100 in the controls,” write the study authors, noting that their findings contrast with data from a small study suggesting that all patients with rheumatic diseases have a response.

They also report in the Annals of the Rheumatic Diseases that antibody responses were delayed in people with IMIDs relative to controls. Analysis of immunogenicity over time illustrated that there was a “relatively large” difference in OD measurements between the two groups in the days following the second vaccination, but this difference “converged over time.”

Moreover, a linear model of group-time interactions showed that the adjusted mean difference in OD between people with IMIDs and controls was a significant 2.21 units at day 28 after the first vaccine dose, decreasing to a nonsignificant 0.07 units at day 70.

“Delayed antibody responses to the SARS-CoV-2 vaccine may suggest an effect of immune-modulatory treatments,” suggest Schett and team. However, they say that “we could not objectify this hypothesis,” because untreated patients with IMIDs (n=24) also had lower antibody responses than healthy controls, and there were “no differences” in antibody responses among those treated with conventional DMARDs (n=20) versus biologics or JAK inhibitors (n=36).

The researchers conclude that although efficacy was “somewhat delayed and reduced” in their study, “the data also show that, in principle, patients with IMID respond to SARS-CoV-2 vaccination, supporting an aggressive vaccination strategy.”

Original research was published in Ann Rheum Dis 2021; doi:10.1136/annrheumdis-2021-220461.

EZorb - Frequently Asked Questions & Answers

EZorb Clinical Studies

Marvlix Benefits

Order Now

EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix.

Back to EZorb Newsletter Index